Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst, Inc. CEO Albert Benjamin reported a mandatory tax-withholding share disposition. On March 10, 2026, he disposed of 70,455 shares of common stock at $1.8481 per share to cover tax obligations tied to vesting restricted stock units.
This “sell to cover” transaction was mandated under the company’s equity incentive plans and is described as not a discretionary trade by Benjamin. After this tax-withholding event, he directly holds 1,457,978 shares of Health Catalyst common stock.
Health Catalyst, Inc. is a healthcare data and analytics company that provides a cloud-based platform, software applications, and expert services to help providers make data-informed clinical, financial, and operational decisions. Its core Ignite platform integrates disparate healthcare data and supports self-service analytics.
As of December 31, 2025, Health Catalyst served 162 Platform Clients and over 1,000 App Clients, largely on subscription contracts. The company reports more than 2,000 documented, client-verified improvements and employs more than 1,200 team members, including over 950 analytics and domain experts. Key risks include intense competition, macroeconomic pressure, cybersecurity, regulatory complexity, AI-related risks, and leverage under its term loan facility.
Health Catalyst, Inc. reported modest 2025 growth but a sharply wider loss driven by non-cash charges. Total revenue for 2025 was $311.1 million, up 1% year over year, while fourth-quarter revenue declined 6% to $74.7 million as professional services fell.
GAAP net loss widened to $177.9 million from $69.5 million, largely due to $110.2 million of goodwill and intangible impairments and higher non-cash expenses. Despite this, profitability metrics improved: gross margin rose to 38.7%, Adjusted Gross Margin to 51.1%, and Adjusted EBITDA increased to $41.4 million from $26.1 million.
Cash and cash equivalents dropped to $50.8 million from $249.6 million, with full-year operating cash flow just positive at $0.7 million. Platform Clients grew to 162 from 130, but Dollar-based Retention Rate (Tech + TEMS) declined to 93% from 102%. For Q1 2026, the company guides to revenue of $68–$70 million and Adjusted EBITDA of $7–$8 million, while it withholds full-year 2026 guidance pending an internal strategic review tied to its CEO transition.
Health Catalyst, Inc. (HCAT) officer Benjamin Albert reported a proposed sale of 70,455 common shares, with an approximate sale date of March 10, 2026, and an aggregate market value of $130,207.89. The shares are listed as restricted stock acquired from Health Catalyst on March 10, 2026, as compensation. Albert also reported sales of 13,304 restricted shares on February 26, 2026, for gross proceeds of $23,252.73, and 4,966 restricted shares on March 2, 2026, for gross proceeds of $8,243.06. Morgan Stanley Smith Barney LLC is named as broker.
Health Catalyst, Inc. General Counsel Benjamin Landry reported a tax-related share disposition. On March 2, 2026, 20,838 shares of common stock were sold at $1.6599 per share to cover tax withholding triggered by the vesting of restricted stock units under the company’s equity incentive plans. The filing notes this “sell to cover” transaction was mandated by the company’s plan election and was not a discretionary trade by Landry. After this transaction, he directly held 378,318 shares of common stock.
Health Catalyst, Inc. Chief Financial Officer Jason Alger disposed of 26,970 shares of common stock at an average price of $1.6599 per share. The shares were sold automatically to cover tax withholding on vested restricted stock units under the company’s equity plans, not as a discretionary trade. After this tax-withholding sale, he holds 741,644 shares directly.
Health Catalyst, Inc. CEO Albert Benjamin reported a Form 4 transaction involving common stock. On March 2, 2026, he disposed of 4,966 shares of common stock at $1.6599 per share as a tax-withholding disposition related to vesting of restricted stock units. This sale was mandated under the company’s equity incentive plan as a “sell to cover” transaction and was not a discretionary trade. Following this transaction, he directly owned 1,528,433 shares of common stock.
Larson-Green Julie reported acquisition or exercise transactions in this Form 4 filing.
Health Catalyst, Inc. director Julie Larson-Green received an equity award of 8,361 restricted stock units (RSUs) of common stock. The RSUs were granted under the company’s 2019 Stock Option and Incentive Plan and each RSU represents a right to one common share. Under the Non-Employee Director Compensation Policy, 100% of these RSUs vested on March 1, 2026. Following this grant, she directly owns 81,934 shares of Health Catalyst common stock.
Health Catalyst, Inc. Chief People Officer Linda Llewelyn reported a tax-related share disposition. On March 2, 2026, 13,836 shares of common stock were disposed of at $1.6599 per share to cover tax withholding tied to restricted stock unit vesting. After this mandated “sell to cover” transaction under the company’s equity incentive plans, she held 329,651 shares directly. The footnote clarifies this was not a discretionary trade.
Health Catalyst, Inc. reported a Form 144 for restricted common stock sales by an individual associated with compensation shares. The filing lists 26,970 restricted shares proposed to be sold on 03/02/2026 through Morgan Stanley Smith Barney LLC on Nasdaq. The filing also discloses prior sales in the past three months: 20,619 shares sold on 12/01/2025 and 7,522 shares sold on 02/26/2026, both identified as restricted stock transactions by Jason Alger.